| Primary |
| Acute Lymphocytic Leukaemia |
39.1% |
| Prophylaxis |
21.7% |
| Neoplasm Malignant |
17.4% |
| Drug Use For Unknown Indication |
13.0% |
| Infection Prophylaxis |
8.7% |
|
| Hepatic Steatosis |
11.8% |
| Staphylococcal Infection |
11.8% |
| White Blood Cell Count Decreased |
11.8% |
| Arthralgia |
5.9% |
| Blood Glucose Increased |
5.9% |
| Depression |
5.9% |
| Dizziness |
5.9% |
| Liver Injury |
5.9% |
| Loss Of Consciousness |
5.9% |
| Pyrexia |
5.9% |
| Syncope |
5.9% |
| Thrombosis |
5.9% |
| Urticaria |
5.9% |
| Ventricular Dysfunction |
5.9% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
62.3% |
| B Precursor Type Acute Leukaemia |
6.2% |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
5.1% |
| T-cell Lymphoma |
3.8% |
| Non-hodgkin's Lymphoma |
2.8% |
| T-cell Type Acute Leukaemia |
2.1% |
| Prophylaxis |
2.0% |
| Central Nervous System Lymphoma |
1.9% |
| Leukaemia |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.4% |
| Acute Lymphoblastic Leukemia |
1.3% |
| Chemotherapy |
1.3% |
| Fungal Infection |
1.2% |
| Malignant Histiocytosis |
1.2% |
| Product Used For Unknown Indication |
1.2% |
| Infection Prophylaxis |
1.0% |
| Lymphocytic Leukaemia |
1.0% |
| Acute Undifferentiated Leukaemia |
0.9% |
| Bone Marrow Conditioning Regimen |
0.9% |
| Lymphoblastic Lymphoma |
0.9% |
|
| Sepsis |
11.1% |
| Posterior Reversible Encephalopathy Syndrome |
8.9% |
| Vomiting |
8.9% |
| Thrombocytopenia |
7.8% |
| White Blood Cell Count Decreased |
7.8% |
| Septic Shock |
6.7% |
| Staphylococcal Infection |
6.7% |
| Stomatitis |
4.4% |
| Unresponsive To Stimuli |
4.4% |
| Death |
3.3% |
| Mucosal Inflammation |
3.3% |
| Multi-organ Failure |
3.3% |
| Off Label Use |
3.3% |
| Pulmonary Embolism |
3.3% |
| Superior Sagittal Sinus Thrombosis |
3.3% |
| Tonic Clonic Movements |
3.3% |
| Venoocclusive Liver Disease |
3.3% |
| Asthenia |
2.2% |
| Chronic Myeloid Leukaemia |
2.2% |
| Hypertriglyceridaemia |
2.2% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
53.2% |
| Antibiotic Prophylaxis |
8.6% |
| Drug Toxicity Prophylaxis |
8.6% |
| Product Used For Unknown Indication |
6.6% |
| Chemotherapy |
4.4% |
| Prophylaxis |
4.2% |
| Acute Lymphocytic Leukaemia Recurrent |
2.2% |
| B Precursor Type Acute Leukaemia |
1.9% |
| Febrile Neutropenia |
1.7% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
| T-cell Type Acute Leukaemia |
1.7% |
| Infection |
1.1% |
| Graft Versus Host Disease |
0.8% |
| Blood Triglycerides Increased |
0.6% |
| Gastritis |
0.6% |
| Insulin Resistance |
0.6% |
| Menorrhagia |
0.6% |
| Supplementation Therapy |
0.6% |
| Abdominal Pain Upper |
0.3% |
| Adverse Event |
0.3% |
|
| Sepsis |
56.9% |
| Haemolytic Anaemia |
3.9% |
| No Therapeutic Response |
3.9% |
| Off Label Use |
3.9% |
| Cholestasis |
2.0% |
| Convulsion |
2.0% |
| Grand Mal Convulsion |
2.0% |
| Hepatic Steatosis |
2.0% |
| Hy's Law Case |
2.0% |
| Ileus Paralytic |
2.0% |
| Klebsiella Infection |
2.0% |
| Neurological Symptom |
2.0% |
| Neurotoxicity |
2.0% |
| Pain In Jaw |
2.0% |
| Paralysis Flaccid |
2.0% |
| Pleural Effusion |
2.0% |
| Pseudomonas Test Positive |
2.0% |
| Pyrexia |
2.0% |
| Renal Failure |
2.0% |
| Renal Failure Acute |
2.0% |
|
